{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T06:22:54Z","timestamp":1783750974700,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The DNA methyltransferase (DNMT) inhibitor 5-fluoro-2\u2019-deoxycytidine (FdCyd) combined with tetrahydrouridine (THU) yielded promising activity in patients with advanced solid tumors, but the intravenous administration schedule of FdCyd limited the clinical feasibility of this treatment program. Therefore, we developed an orally bioavailable formulation of FdCyd and determined the safety, recommended phase 2 dose (RP2D), pharmacokinetics, molecular pharmacodynamic (PD) effects, and antitumor activity of this agent combined with THU.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult patients with advanced solid tumors received FdCyd and THU orally on an intermittent schedule in 21-day cycles; dose levels included once- or twice-daily dosing administered on the first 3\u20137 days (depending on the dose level) of weeks 1 and 2 of each cycle, with no administration on week 3. Dose escalation followed a standard 3\u2009+\u20093 design; doses were increased until the target FdCyd maximum plasma concentration corresponding to DNMT inhibition in preclinical studies (1 \u00b5M) was reached, after which, the total dose was escalated by increasing the number of days and\/or frequency of FdCyd-THU administration. Blood specimens were collected for pharmacokinetic analysis and circulating tumor cell (CTC) PD analyses. Paired pre- and on-treatment (cycle 1 week 3) tumor biopsies were collected during the expansion phase to assess changes in expression of DNMT1 and the epigenetically regulated tumor suppressor protein p16 by immunohistochemistry (IHC), as well as changes in genome-wide DNA promoter methylation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty-nine patients with solid tumors were enrolled. The RP2D was 160\u00a0mg FdCyd once daily combined with 3000\u00a0mg THU once daily on days 1\u20136 and 8\u201313 of each 21-day cycle. Dose-limiting toxicities (DLT) were grade 3 diarrhea and grade 3 refractory nausea, vomiting, and diarrhea; the most common grade 3\u20134 adverse events were hematological toxicities. The best response was prolonged stable disease (17 cycles). Active FdCyd plasma concentrations were achieved at doses of 60\u00a0mg and higher, and THU exposure was associated with DLT. One of the 7 patients (14%) with analyzable paired tumor biopsy specimens exhibited an appreciable increase in tumor p16 expression, and none had appreciable decreases in qualitative tumor DNMT1 levels. An increase in the proportion of p16-expressing cytokeratin-positive (CK\n                      <jats:sup>+<\/jats:sup>\n                      ) CTCs was detected in 77% of patients (23 of 30) evaluable for CK\n                      <jats:sup>+<\/jats:sup>\n                      CTC response, while that for vimentin-positive (V\n                      <jats:sup>+<\/jats:sup>\n                      ) CTCs was 9% of patients (2 of 22) evaluable for V\n                      <jats:sup>+<\/jats:sup>\n                      CTC response. Patients with paired biopsies and a best response of stable disease showed treatment-induced promoter hypomethylation for several epigenetically regulated genes, including tumor suppressor genes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We determined the RP2D for the combination of orally administered FdCyd and THU and measured prolonged stable disease and tumor suppressor gene hypomethylation in some patients, suggesting potential clinical benefit and molecular activity for this regimen in some patients. The paucity of tumor DNMT1 decreases and p16 re-expression are consistent with the lack of clinical response. However, it may also reflect the timing of on-treatment biopsies (following the 1-week break in FdCyd administration), since increases in p16-expressing CTCs were measured for the majority of CTC-assessable patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00280-025-04844-y","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T05:54:15Z","timestamp":1766382855000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A phase 1 study of orally administered 5-fluoro-2\u2019-deoxycytidine with tetrahydrouridine in patients with refractory solid tumors"],"prefix":"10.1007","volume":"96","author":[{"given":"Alice P.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivaani","family":"Kummar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Rubinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Zlott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine O\u2019Sullivan","family":"Coyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-Josef","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza C.","family":"Villaruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam M.","family":"Konat\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine V.","family":"Ferry-Galow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Kinders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph E.","family":"Parchment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Covey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianne L.","family":"Holleran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Piekarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamin","family":"Juwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.","family":"Beumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Doroshow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"4844_CR1","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1056\/NEJMra023075","volume":"349","author":"JG Herman","year":"2003","unstructured":"Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042\u20132054. https:\/\/doi.org\/10.1056\/NEJMra023075","journal-title":"N Engl J Med"},{"key":"4844_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108640","volume":"258","author":"AV Lee","year":"2024","unstructured":"Lee AV, Nestler KA, Chiappinelli KB (2024) Therapeutic targeting of DNA methylation alterations in cancer. Pharmacol Ther 258:108640. https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108640","journal-title":"Pharmacol Ther"},{"key":"4844_CR3","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1634\/theoncologist.2012-0465","volume":"18","author":"EJB Derissen","year":"2013","unstructured":"Derissen EJB, Beijnen JH, Schellens JHM (2013) Concise drug review: Azacitidine and decitabine. Oncologist 18:619\u2013624. https:\/\/doi.org\/10.1634\/theoncologist.2012-0465","journal-title":"Oncologist"},{"key":"4844_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2217\/epi.09.44","volume":"2","author":"LA Cowan","year":"2010","unstructured":"Cowan LA, Talwar S, Yang AS (2010) Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with Azacitidine and decitabine in solid tumors. Epigenomics 2:71\u201386. https:\/\/doi.org\/10.2217\/epi.09.44","journal-title":"Epigenomics"},{"key":"4844_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/ppo.0000000000000278","volume":"23","author":"EM Da Costa","year":"2017","unstructured":"Da Costa EM, McInnes G, Beaudry A, Raynal NJ (2017) DNA methylation-targeted drugs. Cancer J 23:270\u2013276. https:\/\/doi.org\/10.1097\/ppo.0000000000000278","journal-title":"Cancer J"},{"key":"4844_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.189066","volume":"1879","author":"C Ye","year":"2024","unstructured":"Ye C, Jiang N, Zheng J, Zhang S, Zhang J, Zhou J (2024) Epigenetic therapy: research progress of decitabine in the treatment of solid tumors. Biochimica et Biophysica Acta (BBA) 1879:189066. https:\/\/doi.org\/10.1016\/j.bbcan.2023.189066","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"3","key":"4844_CR7","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00280-014-2674-7","volume":"75","author":"EM Newman","year":"2015","unstructured":"Newman EM, Morgan RJ, Kummar S, Beumer JH, Blanchard MS et al (2015) A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2\u2019-deoxycytidine, administered with tetrahydrouridine. Cancer Chemother Pharmacol 75(3):537\u2013546. https:\/\/doi.org\/10.1007\/s00280-014-2674-7","journal-title":"Cancer Chemother Pharmacol"},{"key":"4844_CR8","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00280-020-04073-5","volume":"85","author":"GO Coyne","year":"2020","unstructured":"Coyne GO, Wang L, Zlott J, Juwara L, Covey JM et al (2020) Intravenous 5-fluoro-2\u2019-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors. Cancer Chemother Pharmacol 85:979\u2013993. https:\/\/doi.org\/10.1007\/s00280-020-04073-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"4844_CR9","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00280-015-2857-x","volume":"76","author":"JL Holleran","year":"2015","unstructured":"Holleran JL, Beumer JH, McCormick DL, Johnson WD, Newman EM et al (2015) Oral and intravenous pharmacokinetics of 5-fluoro-2\u2019-deoxycytidine and THU in cynomolgus monkeys and humans. Cancer Chemother Pharmacol 76:803\u2013811. https:\/\/doi.org\/10.1007\/s00280-015-2857-x","journal-title":"Cancer Chemother Pharmacol"},{"key":"4844_CR10","first-page":"4534","volume":"46","author":"J Kaysen","year":"1986","unstructured":"Kaysen J, Spriggs D, Kufe D (1986) Incorporation of 5-fluorodeoxycytidine and metabolites into nucleic acids of human MCF-7 breast carcinoma cells. Cancer Res 46:4534\u20134538","journal-title":"Cancer Res"},{"key":"4844_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"4844_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00280-007-0603-8","volume":"62","author":"JH Beumer","year":"2008","unstructured":"Beumer JH, Parise RA, Newman EM, Doroshow JH, Synold TW et al (2008) Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2\u2032-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). Cancer Chemother Pharmacol 62:363\u2013368. https:\/\/doi.org\/10.1007\/s00280-007-0603-8","journal-title":"Cancer Chemother Pharmacol"},{"key":"4844_CR13","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1158\/1078-0432.Ccr-18-2523","volume":"25","author":"DF Wilsker","year":"2019","unstructured":"Wilsker DF, Barrett AM, Dull AB, Lawrence SM, Hollingshead MG et al (2019) Evaluation of pharmacodynamic responses to cancer therapeutic agents using DNA damage markers. Clin Cancer Res 25:3084\u20133095. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-2523","journal-title":"Clin Cancer Res"},{"key":"4844_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40484-019-0183-8","volume":"7","author":"H Feng","year":"2019","unstructured":"Feng H, Wu H (2019) Differential methylation analysis for bisulfite sequencing using DSS. Quant Biol 7:327\u2013334. https:\/\/doi.org\/10.1007\/s40484-019-0183-8","journal-title":"Quant Biol"},{"key":"4844_CR15","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1093\/bioinformatics\/btx183","volume":"33","author":"RG Cavalcante","year":"2017","unstructured":"Cavalcante RG, Sartor MA (2017) Annotatr: genomic regions in context. Bioinformatics 33:2381\u20132383. https:\/\/doi.org\/10.1093\/bioinformatics\/btx183","journal-title":"Bioinformatics"},{"key":"4844_CR16","doi-asserted-by":"publisher","first-page":"D1083","DOI":"10.1093\/nar\/gkaa968","volume":"49","author":"A Luna","year":"2021","unstructured":"Luna A, Elloumi F, Varma S, Wang Y, Rajapakse VN et al (2021) CellMiner cross-database (CellMinerCDB) version 1.2: exploration of patient-derived cancer cell line pharmacogenomics. Nucleic Acids Res 49:D1083-d1093. https:\/\/doi.org\/10.1093\/nar\/gkaa968","journal-title":"Nucleic Acids Res"},{"key":"4844_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen EY, Tan CM, Kou Y, Duan Q, Wang Z et al (2013) Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14:128. https:\/\/doi.org\/10.1186\/1471-2105-14-128","journal-title":"BMC Bioinformatics"},{"key":"4844_CR18","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q et al (2016) Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res 44:W90\u2013W97. https:\/\/doi.org\/10.1093\/nar\/gkw377","journal-title":"Nucleic Acids Res"},{"key":"4844_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.90","volume":"1","author":"Z Xie","year":"2021","unstructured":"Xie Z, Bailey A, Kuleshov MV, Clarke DJB, Evangelista JE et al (2021) Gene set knowledge discovery with Enrichr. Curr Protoc 1:e90. https:\/\/doi.org\/10.1002\/cpz1.90","journal-title":"Curr Protoc"},{"key":"4844_CR20","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1093\/nar\/gkq187","volume":"38","author":"K Patel","year":"2010","unstructured":"Patel K, Dickson J, Din S, Macleod K, Jodrell D, Ramsahoye B (2010) Targeting of 5-aza-2\u2019-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. Nucleic Acids Res 38:4313\u20134324. https:\/\/doi.org\/10.1093\/nar\/gkq187","journal-title":"Nucleic Acids Res"},{"key":"4844_CR21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00280-014-2503-z","volume":"74","author":"JV Thottassery","year":"2014","unstructured":"Thottassery JV, Sambandam V, Allan PW, Maddry JA, Maxuitenko YY et al (2014) Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4\u2019-thio-2\u2019-deoxycytidine and 5-aza-4\u2019-thio-2\u2019-deoxycytidine. Cancer Chemother Pharmacol 74:291\u2013302. https:\/\/doi.org\/10.1007\/s00280-014-2503-z","journal-title":"Cancer Chemother Pharmacol"},{"key":"4844_CR22","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1158\/1078-0432.Ccr-08-2859","volume":"15","author":"R Plummer","year":"2009","unstructured":"Plummer R, Vidal L, Griffin M, Lesley M, de Bono J et al (2009) Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. Clin Cancer Res 15:3177\u20133183. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-08-2859","journal-title":"Clin Cancer Res"},{"key":"4844_CR23","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.bbrc.2019.02.017","volume":"511","author":"C Lai","year":"2019","unstructured":"Lai C, Gao J, Zhu Z, Yuan J, Zhang W, Yang J (2019) DNA methyltransferase expression and DNA hypomethylation status in human hepatocytes following trichloroacetic acid exposure. Biochem Biophys Res Commun 511:266\u2013273. https:\/\/doi.org\/10.1016\/j.bbrc.2019.02.017","journal-title":"Biochem Biophys Res Commun"},{"key":"4844_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-32509-4","volume":"13","author":"ABA Laranjeira","year":"2023","unstructured":"Laranjeira ABA, Hollingshead MG, Nguyen D, Kinders RJ, Doroshow JH, Yang SX (2023) DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors. Sci Rep 13:5964. https:\/\/doi.org\/10.1038\/s41598-023-32509-4","journal-title":"Sci Rep"},{"key":"4844_CR25","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1128\/MCB.01799-07","volume":"28","author":"SS Palii","year":"2008","unstructured":"Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD (2008) DNA methylation inhibitor 5-Aza-2\u2032-Deoxycytidine induces reversible Genome-Wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol 28:752\u2013771. https:\/\/doi.org\/10.1128\/MCB.01799-07","journal-title":"Mol Cell Biol"},{"key":"4844_CR26","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1053\/j.seminoncol.2016.06.004","volume":"43","author":"L Wang","year":"2016","unstructured":"Wang L, Balasubramanian P, Chen AP, Kummar S, Evrard YA, Kinders RJ (2016) Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells. Semin Oncol 43:464\u2013475. https:\/\/doi.org\/10.1053\/j.seminoncol.2016.06.004","journal-title":"Semin Oncol"},{"key":"4844_CR27","first-page":"1211","volume":"11","author":"GA Otterson","year":"1995","unstructured":"Otterson GA, Khleif SN, Chen W, Coxon AB, Kaye FJ (1995) CDKN2 gene Silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2\u2019deoxycytidine. Oncogene 11:1211\u20131216","journal-title":"Oncogene"},{"key":"4844_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3506874","volume":"2018","author":"A Milano","year":"2018","unstructured":"Milano A, Mazzetta F, Valente S, Ranieri D, Leone L et al (2018) Molecular detection of EMT markers in circulating tumor cells from metastatic non-small cell lung cancer patients: potential role in clinical practice. Anal Cell Pathol (Amst) 2018:3506874. https:\/\/doi.org\/10.1155\/2018\/3506874","journal-title":"Anal Cell Pathol (Amst)"},{"key":"4844_CR29","doi-asserted-by":"publisher","first-page":"4731","DOI":"10.1158\/0008-5472.Can-17-2459","volume":"78","author":"LN Qi","year":"2018","unstructured":"Qi LN, Xiang BD, Wu FX, Ye JZ, Zhong JH et al (2018) Circulating tumor cells undergoing EMT provide a metric for diagnosis and prognosis of patients with hepatocellular carcinoma. Cancer Res 78:4731\u20134744. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-2459","journal-title":"Cancer Res"},{"key":"4844_CR30","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.18632\/oncotarget.6613","volume":"7","author":"K Dai","year":"2016","unstructured":"Dai K, Qin F, Zhang H, Liu X, Guo C et al (2016) Low expression of BMPRIB indicates poor prognosis of breast cancer and is insensitive to taxane-anthracycline chemotherapy. Oncotarget 7:4770\u20134784. https:\/\/doi.org\/10.18632\/oncotarget.6613","journal-title":"Oncotarget"},{"key":"4844_CR31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1471-2407-6-48","volume":"6","author":"JR Caldeira","year":"2006","unstructured":"Caldeira JR, Prando EC, Quevedo FC, Neto FA, Rainho CA, Rogatto SR (2006) CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer 6:48. https:\/\/doi.org\/10.1186\/1471-2407-6-48","journal-title":"BMC Cancer"},{"key":"4844_CR32","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.18632\/oncotarget.13869","volume":"8","author":"R Swiercz","year":"2017","unstructured":"Swiercz R, Mo M, Khare P, Schneider Z, Ober RJ, Ward ES (2017) Loss of expression of the recycling receptor, FcRn, promotes tumor cell growth by increasing albumin consumption. Oncotarget 8:3528\u20133541. https:\/\/doi.org\/10.18632\/oncotarget.13869","journal-title":"Oncotarget"},{"key":"4844_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijbiomac.2018.11.028","volume":"124","author":"Y Chen","year":"2019","unstructured":"Chen Y, Wang Q, Wang M, Li M (2019) Overexpressed LRIG3 gene ameliorates prostate cancer through suppression of cell invasion and migration. Int J Biol Macromol 124:1\u20139. https:\/\/doi.org\/10.1016\/j.ijbiomac.2018.11.028","journal-title":"Int J Biol Macromol"},{"key":"4844_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12883","volume":"53","author":"H Lee","year":"2020","unstructured":"Lee H, Park BC, Soon Kang J, Cheon Y, Lee S, Jae Maeng P (2020) MAM domain containing 2 is a potential breast cancer biomarker that exhibits tumour-suppressive activity. Cell Prolif 53:e12883. https:\/\/doi.org\/10.1111\/cpr.12883","journal-title":"Cell Prolif"},{"key":"4844_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2169-x","volume":"10","author":"F Dubois","year":"2019","unstructured":"Dubois F, Bergot E, Zalcman G, Levallet G (2019) RASSF1A, puppeteer of cellular homeostasis, fights tumorigenesis, and metastasis\u2014an updated review. Cell Death Dis 10:928. https:\/\/doi.org\/10.1038\/s41419-019-2169-x","journal-title":"Cell Death Dis"},{"key":"4844_CR36","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1038\/onc.2014.356","volume":"34","author":"F Neri","year":"2015","unstructured":"Neri F, Dettori D, Incarnato D, Krepelova A, Rapelli S et al (2015) TET1 is a tumour suppressor that inhibits colon cancer growth by derepressing inhibitors of the WNT pathway. Oncogene 34:4168\u20134176. https:\/\/doi.org\/10.1038\/onc.2014.356","journal-title":"Oncogene"},{"key":"4844_CR37","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1038\/onc.2013.174","volume":"33","author":"E Okochi-Takada","year":"2014","unstructured":"Okochi-Takada E, Hattori N, Tsukamoto T, Miyamoto K, Ando T et al (2014) ANGPTL4 is a secreted tumor suppressor that inhibits angiogenesis. Oncogene 33:2273\u20132278. https:\/\/doi.org\/10.1038\/onc.2013.174","journal-title":"Oncogene"},{"key":"4844_CR38","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41388-019-0985-1","volume":"39","author":"J Joseph","year":"2020","unstructured":"Joseph J, Radulovich N, Wang T, Raghavan V, Zhu CQ, Tsao MS (2020) Rho guanine nucleotide exchange factor ARHGEF10 is a putative tumor suppressor in pancreatic ductal adenocarcinoma. Oncogene 39:308\u2013321. https:\/\/doi.org\/10.1038\/s41388-019-0985-1","journal-title":"Oncogene"},{"key":"4844_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/srep07545","volume":"4","author":"M Shi","year":"2014","unstructured":"Shi M, Wang S, Yao Y, Li Y, Zhang H et al (2014) Biological and clinical significance of epigenetic silencing of MARVELD1 gene in lung cancer. Sci Rep 4:7545. https:\/\/doi.org\/10.1038\/srep07545","journal-title":"Sci Rep"},{"key":"4844_CR40","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/15548627.2021.2008693","volume":"18","author":"X Chao","year":"2022","unstructured":"Chao X, Ni HM, Ding WX (2022) An unexpected tumor suppressor role of SQSTM1\/p62 in liver tumorigenesis. Autophagy 18:459\u2013461. https:\/\/doi.org\/10.1080\/15548627.2021.2008693","journal-title":"Autophagy"},{"key":"4844_CR41","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1158\/1541-7786.Mcr-17-0227","volume":"16","author":"D Kim","year":"2018","unstructured":"Kim D, Shivakumar M, Han S, Sinclair MS, Lee YJ et al (2018) Population-dependent intron retention and DNA methylation in breast cancer. Mol Cancer Res 16:461\u2013469. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-17-0227","journal-title":"Mol Cancer Res"},{"key":"4844_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-020-00888-4","volume":"12","author":"AR Nam","year":"2020","unstructured":"Nam AR, Lee K-H, Hwang H-J, Schabort JJ, An J-H et al (2020) Alternative methylation of intron motifs is associated with cancer-related gene expression in both canine mammary tumor and human breast cancer. Clin Epigenetics 12:110. https:\/\/doi.org\/10.1186\/s13148-020-00888-4","journal-title":"Clin Epigenetics"},{"key":"4844_CR43","doi-asserted-by":"publisher","first-page":"5972","DOI":"10.1038\/s41388-021-01990-4","volume":"40","author":"M Mu","year":"2021","unstructured":"Mu M, Niu W, Zhang X, Hu S, Niu C (2021) LncRNA BCYRN1 inhibits glioma tumorigenesis by competitively binding with miR-619-5p to regulate CUEDC2 expression and the PTEN\/AKT\/p21 pathway. Oncogene 40:5972\u20135973. https:\/\/doi.org\/10.1038\/s41388-021-01990-4","journal-title":"Oncogene"},{"key":"4844_CR44","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.40396","author":"SN Udden","year":"2019","unstructured":"Udden SN, Kwak YT, Godfrey V, Khan MAW, Khan S et al (2019) NLRP12 suppresses hepatocellular carcinoma via downregulation of cJun N-terminal kinase activation in the hepatocyte. Elife. https:\/\/doi.org\/10.7554\/eLife.40396","journal-title":"Elife"},{"key":"4844_CR45","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/sj.onc.1206141","volume":"22","author":"FP Silva","year":"2003","unstructured":"Silva FP, Morolli B, Storlazzi CT, Anelli L, Wessels H et al (2003) Identification of RUNX1\/AML1 as a classical tumor suppressor gene. Oncogene 22:538\u2013547. https:\/\/doi.org\/10.1038\/sj.onc.1206141","journal-title":"Oncogene"},{"key":"4844_CR46","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/0163-7258(90)90056-8","volume":"48","author":"WB Parker","year":"1990","unstructured":"Parker WB, Cheng YC (1990) Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 48:381\u2013395. https:\/\/doi.org\/10.1016\/0163-7258(90)90056-8","journal-title":"Pharmacol Ther"},{"key":"4844_CR47","doi-asserted-by":"publisher","first-page":"6539","DOI":"10.1021\/jm901869w","volume":"53","author":"D Garg","year":"2010","unstructured":"Garg D, Henrich S, Salo-Ahen OMH, Myllykallio H, Costi MP, Wade RC (2010) Novel approaches for targeting thymidylate synthase to overcome the resistance and toxicity of anticancer drugs. J Med Chem 53:6539\u20136549. https:\/\/doi.org\/10.1021\/jm901869w","journal-title":"J Med Chem"},{"key":"4844_CR48","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1177\/10781552241238979","volume":"30","author":"R Haumschild","year":"2024","unstructured":"Haumschild R, Kennerly-Shah J, Barbarotta L, Zeidan AM (2024) Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes\/neoplasms and acute myeloid leukemia: A multidisciplinary review. J Oncol Pharm Pract 30:721\u2013736. https:\/\/doi.org\/10.1177\/10781552241238979","journal-title":"J Oncol Pharm Pract"},{"key":"4844_CR49","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S2352-3026(23)00338-1","volume":"11","author":"G Garcia-Manero","year":"2024","unstructured":"Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM et al (2024) Oral decitabine\u2013cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol 11:e15\u2013e26. https:\/\/doi.org\/10.1016\/S2352-3026(23)00338-1","journal-title":"Lancet Haematol"},{"key":"4844_CR50","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1200\/jco.2010.34.4226","volume":"29","author":"G Garcia-Manero","year":"2011","unstructured":"Garcia-Manero G, Gore SD, Cogle C, Ward R, Shi T et al (2011) Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 29:2521\u20132527. https:\/\/doi.org\/10.1200\/jco.2010.34.4226","journal-title":"J Clin Oncol"},{"key":"4844_CR51","doi-asserted-by":"publisher","first-page":"5566","DOI":"10.1021\/bi200642e","volume":"50","author":"J Li","year":"2011","unstructured":"Li J, Poi MJ, Tsai M-D (2011) Regulatory mechanisms of tumor suppressor P16INK4A and their relevance to cancer. Biochemistry 50:5566\u20135582. https:\/\/doi.org\/10.1021\/bi200642e","journal-title":"Biochemistry"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04844-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04844-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04844-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T02:57:46Z","timestamp":1771469866000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04844-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4844"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04844-y","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"24 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct the Supplementary file","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the National Institutes of Health and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Shivaani Kummar: Consultant\/Advisory board: Springworks Therapeutics, SeaGen, Bayer, Genome & Company, HarbourBiomed, BPGbio Therapeutics, Oxford Biotherapeutics, Mundibiopharma, BPGbio, Inc., Gilead, Mirati; GI Innovation Inc, XYone Therapeutics, Genome Insight, Aadi Biosciences, MOMA Therapeutics, Daiichi Sankyo, Parabilis, Boehringer Ingelheim Pharmaceuticals, PATHOMIQ (co-founder), Fortress Biotech, Inc (equity), Sift Biosciences (equity). All other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}